During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

Whereas the postsynaptic antagonist actions of OPC-4392 are ... conducted at each of the known molecular isoforms of the dopamine receptors in several transfection systems, as well as at novel ...